Who are AltruBio's investors?

AltruBio's investors include aMoon, Delos Capital, RA Capital, Biotechnology Value Fund, Soleus Capital.

How much funding has AltruBio raised?

AltruBio has disclosed $225M raised across 1 of its 2 known rounds.

AltruBio

8 known investors

Find your way into AltruBio

Paths you didn't know you had: your email and LinkedIn already hold routes to the AltruBio team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease. Its programs are in preclinical through Phase II development.

Biotech Healthtech

Investors · 8

aMoonlisted by aMoonRa'anana

How we know: aMoon's portfolio page · a partner's Signal profile · Not right? Tell us

Delos Capitallisted by Delos CapitalCambridge

How we know: funding news · deloscapital.com · Not right? Tell us

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · funding news · deloscapital.com · Not right? Tell us

Biotechnology Value FundreportedSan Francisco

How we know: funding news · fiercebiotech.com · Not right? Tell us

Soleus CapitalreportedGreenwich

How we know: funding news · deloscapital.com · Not right? Tell us

Also in the syndicate · 3

aMoon FundleadBlackstone Multi-Asset InvestingCormorant Asset Management

Funding

SEC filings, press & company announcements

$225M disclosed across 1 of 2 rounds · 2021–2024

$225MSeries BMay 2024 · 5 sources
aMoon Fund (lead), BVF Partners (lead), Blackstone Multi-Asset Investing, Cormorant Asset Management, Delos Capital, RA Capital Management, Soleus Capital
Source ↗
Undisclosed amountSeries AApr 2021
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

AltruBio Secures Up To $225M Series B Financingfinsmes.com · May 2024

AltruBio Raises $63 Million Series A Round To Continue Its Company Transformationglobenewswire.com · Apr 2021

Frequently asked questions

What does AltruBio do?: AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease. Its programs are in preclinical through Phase II development.
Who are AltruBio's investors?: AltruBio's investors include aMoon, Delos Capital, RA Capital, Biotechnology Value Fund, Soleus Capital.
How much funding has AltruBio raised?: AltruBio has disclosed $225M raised across 1 of its 2 known rounds.